CERS · Cerus Corp
$2.79
-0.06 (-2.11%)
At close · Aug 20
Market Cap
$556.21M
Shares
201.52M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.79
Open$2.82
Day$2.77–2.89
52W close$1.16–3.28
Avg vol 30d2.7M
Short int15.0M · 7.4% float · 5.7d
Short vol50%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 30, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+21%
above
Price vs 50-day avg
−1%
below
RSI (14)
52
neutral
MACD trend
Positive
52-week position
77%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−3%
trailing
6-month return
+9%
trailing
YTD return
+35%
this year
Relative strength
−2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +34 funds added
Insider flow
Distributing
Net -$53.2K over 90 days · 100% sells
Short interest
Rising
7.42% of float · ▲ +9.3% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
183 holders — near 3-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+31%
Y/Y
Gross margin
33%
expanding
EPS growth
+27%
Y/Y
Free cash flow
$1.1M
Balance sheet
$15.1M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−38%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Product revenue
· full-year 2026
Raised
$229M – $231M
Jan 12, 2026
$224M – $228M
changed to
Jul 30, 2026
$229M – $231M
IFC revenue
· full-year 2026
Initiated
$23M – $25M
IFC sales growth
· full-year 2026
Initiated
40% – 50%
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Product revenue
· full-year 2025
$202M – $204M
IFC revenue
· full-year 2025
$16M – $17M
Guided vs delivered
· last 2 settled
Overall product revenue
full year 2024
guided $172M – $175M
$201.32M
Beat +16.0%
Full-year 2023 product revenue
full-year 2023
guided $160M – $165M
$186.8M
Beat +15.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+21%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
77%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +34 funds added
Insider flow
Distributing
Net -$53.2K over 90 days · 100% sells
Short interest
Rising
7.42% of float · ▲ +9.3% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
183 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $3 · 77%
Range high $3
vs 200-day avg +21%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Change in Calculated Number of Treatable Platelet Doses | 6% | Six Months Ended June 30, 2026 vs. 2025 | — |
| Non-GAAP adjusted EBITDA non-GAAP | $7M | first half of 2026 | — |
|
|
|||
| Platelet Kit Growth | 5% | Six Months Ended June 30, 2026 vs. 2025 | — |
| Platelet Kit Growth - North America | 2% | second quarter of 2026 | — |
| Product gross margin | 51.4% | second quarter of 2026 | — |
| Product gross profit | $29.5M | second quarter of 2026 | — |
| Total IFC Demand Growth | 50% | Six Months Ended June 30, 2026 vs. 2025 | — |
| U.S. IFC sales | $6.7M | second quarter of 2026 | — |
| IFC product revenue (preliminary) | $16.7M | FY2025 | — |
| INTERCEPT treated blood component doses | 3M | FY2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CERS
this stock
Cerus Corp
|
$556.21M | +35.4% | +30.7% | — | 7.4% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$120.49B | -3.9% | +8.4% | 25.2 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.14B | -48.2% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CERS | -1.8% | -2.8% | +9.0% | +29.8% | +35.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +0.2% | -6.1% | -2.2% | +27.7% | +23.6% |
Key facts
CIK
1020214
CUSIP
157085101
13F (30d)
170 filings
166 filers
Visit website
Investor relations